- First ask: what is the indication, and for how long? The indication picks the drug, the dose and the target.
- IV heparin is not one dose. VTE = 80 U/kg bolus → 18 U/kg/h. ACS = 60 U/kg (max 4000) → 12 U/kg/h (max 1000). Prophylaxis = 5000 U SC q8–12h (fixed).
- Most patients → a DOAC. Warfarin still wins for mechanical valves, moderate–severe rheumatic mitral stenosis, triple-positive APS (and often dialysis, LVAD).
- Starting warfarin for a clot? Overlap heparin ≥5 days AND INR ≥2 for 24 h — the 5-and-2 rule.
- High INR, no bleeding → hold doses. INR >10 → add vitamin K 2.5–5 mg PO. Major bleed → 4F-PCC + vitamin K 5–10 mg IV.
- Bridging is the exception. No bridge for AF or for DOACs. Bridge only the patient in a VEST (see below).
- Andexanet (Andexxa) is gone from the US (Dec 2025). Xa-inhibitor bleed → 4F-PCC.
Pathophysiology in 60 seconds
⌄
- Clotting is a relay race that ends with thrombin (IIa) turning fibrinogen into a fibrin net.
- Xa makes thrombin. Block Xa or IIa and the net does not form.
- Heparins do not act alone. They turbo-charge antithrombin (AT), which then kills Xa and IIa.
- UFH: Xa = IIa (long chains grab both). LMWH: mostly Xa. Fondaparinux: Xa only.
- DOACs block one target directly (no AT needed): Xa (apixaban, rivaroxaban, edoxaban) or IIa (dabigatran).
- Warfarin blocks vitamin K recycling in the liver → the liver makes non-working II, VII, IX, X — and also protein C and S (the natural anticoagulants).
UFH hits Xa and IIa equally; LMWH mostly Xa; fondaparinux only Xa. That is why only UFH is fully reversed by protamine, and why anti-Xa levels read falsely high after apixaban or rivaroxaban.
- WEPT — Warfarin → Extrinsic pathway → PT/INR
- HIP — Heparin → Intrinsic pathway → aPTT (or anti-Xa)
- Warfarin factors = "1972": 10, 9, 7, 2 (+ protein C and S).
Who needs it, and for how long?
⌄
| Indication | Usual drug | Duration / target |
|---|---|---|
| AF / flutter — CHA₂DS₂-VASc ≥2 (men) / ≥3 (women) | DOAC | Long term (risk does not go away after sinus rhythm) |
| AF — score 1 (men) / 2 (women) | DOAC reasonable | Shared decision |
| Cardioversion, AF ≥48 h or unknown | DOAC or warfarin | 3 weeks before (or TEE) + ≥4 weeks after |
| VTE provoked by a major transient factor (surgery, trauma) | DOAC | 3 months |
| VTE unprovoked or persistent risk factor | DOAC | 3 months, then usually extended if bleeding risk OK (apixaban 2.5 BID / rivaroxaban 10 daily) |
| Cancer-associated VTE | Apixaban, rivaroxaban, edoxaban or LMWH | ≥6 months, while cancer is active |
| Isolated distal DVT, low risk, no symptoms | — | Serial ultrasound × 2 weeks, or 3 months |
| Mechanical aortic valve (bileaflet, no risk factor) | Warfarin | Lifelong, INR 2.5 (2.0–3.0) |
| Mechanical mitral valve, or aortic + risk factor* | Warfarin | Lifelong, INR 3.0 (2.5–3.5) |
| On-X aortic valve | Warfarin + aspirin | INR 2.5 for 3 months, then 1.5–2.0 |
| Surgical bioprosthetic valve | Warfarin (or aspirin) | 3–6 months, if low bleeding risk |
| LV thrombus after MI | Warfarin or DOAC | 3–6 months → re-image |
| Triple-positive APS | Warfarin INR 2–3 | Lifelong |
| Superficial vein thrombosis ≥5 cm | Fondaparinux 2.5 mg daily | 45 days |
*Risk factors for valves: AF, prior thromboembolism, LV dysfunction, hypercoagulable state, older caged-ball or tilting-disc valve.
- ACC/AHA 2023: anticoagulate if annual stroke risk ≥2% — CHA₂DS₂-VASc ≥2 men / ≥3 women. Score is a start; other risk tools are allowed.
- ESC 2024: drops sex → CHA₂DS₂-VA. ≥2 → recommended, 1 → consider.
- Never use aspirin as a "softer" option for stroke prevention in AF.
- Wrong valve for a DOAC: mechanical valve, moderate–severe rheumatic mitral stenosis
- Antiphospholipid syndrome — triple-positive or arterial events
- Renal failure — CrCl <15 / dialysis (apixaban is the DOAC alternative)
- Few other options — LVAD, strong inducers (rifampin, carbamazepine, phenytoin), bariatric surgery / poor absorption, cost
Heparin (UFH) — dose by indication
⌄
Three dials, three indications. The clot you treat picks the nomogram: an arterial clot on a stent needs less heparin (plus antiplatelets) than a big venous clot. AF, valves and bridging use the low-intensity "cardiac" nomogram, often with no bolus.
| Indication | Weight-based? | Bolus | Start rate | Target |
|---|---|---|---|---|
| VTE treatment (DVT, PE) | Yes — actual weight | 80 U/kg | 18 U/kg/h | anti-Xa 0.3–0.7 (aPTT ≈ 1.5–2.5× control) |
| ACS (NSTE-ACS, STEMI + lytic) | Yes, capped | 60 U/kg (max 4000) | 12 U/kg/h (max 1000) | anti-Xa 0.3–0.7 (aPTT ≈ 1.5–2×) |
| PCI (cath lab) | Yes | 70–100 U/kg (50–70 with GP IIb/IIIa) | — | ACT 250–300 (200–250 with GPI) |
| AF, mechanical valve, LV thrombus, bridging ("cardiac / low-intensity" nomogram) | Yes | None or small — no bolus after a stroke or if bleeding risk | 12–18 U/kg/h per local nomogram | anti-Xa 0.3–0.7 |
| VTE prophylaxis | No — fixed | — | 5000 U SC q8h or q12h; BMI ≥40 → 7500 U SC q8h | No monitoring |
| VTE treatment, SC, no monitoring (FIDO) | Yes | 333 U/kg SC | then 250 U/kg SC q12h | None |
| VTE, old fixed-dose IV | No | 5000 U | 1000 U/h | aPTT — weight-based is better |
- Weight: use actual body weight. Many protocols cap the VTE bolus (~10,000 U) and start rate (~2000 U/h) — follow your nomogram.
- When to choose UFH over LMWH/DOAC: CrCl <30, may need lysis or a procedure soon (short half-life ~60–90 min), very high bleeding risk, hemodynamically unstable PE.
Raschke weight-based nomogram — aPTT checked 6 h after start and after every change.
| aPTT | Bolus | Rate change |
|---|---|---|
| <1.2× control (<35 s) | 80 U/kg | ↑ 4 U/kg/h |
| 1.2–1.5× (35–45 s) | 40 U/kg | ↑ 2 U/kg/h |
| 1.5–2.3× (46–70 s) | — | No change |
| 2.3–3× (71–90 s) | — | ↓ 2 U/kg/h |
| >3× (>90 s) | Hold 1 h | ↓ 3 U/kg/h |
- The seconds come from the original study. Your lab's therapeutic range is different — use the hospital nomogram.
- Two therapeutic values in a row → check daily.
| Problem | aPTT | Anti-Xa |
|---|---|---|
| Recent apixaban / rivaroxaban (last 2–3 days) | ||
| Lupus anticoagulant, factor XII deficiency, warfarin overlap | ||
| Acute illness, high factor VIII / fibrinogen | ||
| High bilirubin or triglycerides |
"Heparin resistance" = needs >35,000 U/day. Check anti-Xa first (often already therapeutic), then antithrombin level.
- Platelets: baseline, then every 2–3 days on days 4–14 → think HIT if they fall >50%.
- Stop 4–6 h before a procedure. Restart (no bolus) 12–24 h after, when hemostasis is OK.
- Reversal — protamine: 1 mg per 100 U of heparin given in the last 2–3 h (max 50 mg), slow IV (hypotension, anaphylaxis — fish allergy, NPH insulin, vasectomy).
LMWH & fondaparinux
⌄
| Use | Enoxaparin | CrCl <30 | Notes |
|---|---|---|---|
| VTE prophylaxis | 40 mg SC daily (30 mg BID ortho/trauma) | 30 mg daily | BMI ≥40 → 40 mg BID (or 0.5 mg/kg daily) |
| VTE treatment | 1 mg/kg q12h | 1 mg/kg daily | 1.5 mg/kg daily is OK in simple VTE — not in cancer or obesity |
| NSTE-ACS | 1 mg/kg q12h | 1 mg/kg daily | |
| STEMI + lytic, age <75 | 30 mg IV + 1 mg/kg SC q12h (max 100 mg first 2 doses) | 1 mg/kg daily | |
| STEMI + lytic, age ≥75 | No bolus, 0.75 mg/kg q12h (max 75 mg first 2 doses) | 1 mg/kg daily |
- Weight-based on actual weight. No label maximum — check anti-Xa if >150 kg, pregnant, CrCl <30, or <45 kg.
- Anti-Xa = 4 h after the 3rd or 4th dose. Target 0.6–1.0 (BID) or 1.0–2.0 (daily).
- Dalteparin (cancer VTE, CLOT): 200 U/kg daily × 1 month → 150 U/kg daily.
- Fondaparinux (Xa only, no HIT risk): prophylaxis 2.5 mg daily. Treatment by weight: <50 kg 5 mg · 50–100 kg 7.5 mg · >100 kg 10 mg daily. Avoid CrCl <30. No antidote.
- Protamine for enoxaparin (only ~60% reversal): given <8 h → 1 mg per 1 mg enoxaparin; 8–12 h → 0.5 mg per 1 mg.
DOACs
⌄
| Drug | AF | VTE treatment | Extended VTE (after 6 mo) | Dose cut |
|---|---|---|---|---|
| Apixaban | 5 mg BID | 10 mg BID × 7 d → 5 mg BID | 2.5 mg BID | AF: 2.5 BID if 2 of 3: age ≥80, weight ≤60 kg, Cr ≥1.5 |
| Rivaroxaban | 20 mg daily with evening meal | 15 mg BID × 21 d → 20 mg daily | 10 mg daily | AF: 15 mg if CrCl 15–50. Take 15/20 mg with food |
| Dabigatran | 150 mg BID | 5–10 d parenteral → 150 mg BID | 150 mg BID | US AF: 75 mg BID if CrCl 15–30. Do not open capsules |
| Edoxaban | 60 mg daily | 5–10 d parenteral → 60 mg daily | — | 30 mg if CrCl 15–50, weight ≤60 kg, or some P-gp inhibitors. AF: avoid if CrCl >95 |
Age ≥80, weight ≤60 kg, creatinine ≥1.5. Two of three → 2.5 mg BID. One alone → keep 5 mg BID. (This rule is for AF only — VTE doses do not change.)
- Mechanical valve (RE-ALIGN: more clots and bleeds with dabigatran) · moderate–severe rheumatic mitral stenosis
- Triple-positive APS · pregnancy / breastfeeding → LMWH
- Strong P-gp + CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St John's wort)
- CrCl <15 (apixaban is the exception — check with pharmacy) · early after bariatric surgery
- Obesity is not a reason to avoid: ISTH 2021 — apixaban or rivaroxaban are fine for VTE at any weight/BMI. Avoid dabigatran and edoxaban if BMI >40 or weight >120 kg.
Switching between drugs
| From → To | How |
|---|---|
| IV UFH → DOAC | Start the DOAC when you stop the drip |
| LMWH → DOAC | Start the DOAC when the next LMWH dose is due |
| DOAC → UFH / LMWH | Start when the next DOAC dose is due (UFH: no bolus; monitor by aPTT, not anti-Xa) |
| Warfarin → DOAC | Stop warfarin. Start when INR <2 (apixaban, dabigatran), <3 (rivaroxaban), ≤2.5 (edoxaban) |
| DOAC → warfarin | Overlap until INR ≥2. Check INR just before the next DOAC dose (DOACs raise the INR) |
Warfarin — start, steer, stay in range
⌄
Starting warfarin
- Baseline: CBC, PT/INR, aPTT, LFTs, creatinine, pregnancy test, full drug list.
- Start dose: 5 mg daily for most inpatients.
- 2.5 mg (or less): age >75, frail, low weight, liver disease, HF, poor intake/NPO, hyperthyroid, amiodarone or other interacting drugs, Asian ancestry, known CYP2C9/VKORC1 variants.
- 10 mg × 2 days only in healthy, stable outpatients with VTE (CHEST).
- INR daily in hospital. After discharge: 3–5 days, then weekly until stable, then every 4 weeks (up to 12 weeks if very stable).
Early INR = factor VII. Real anticoagulation = factor II. Protein C (a natural anticoagulant) falls in hours → overlap heparin in acute clots and HIT.
Heparin/LMWH + warfarin together for at least 5 days AND until INR ≥2 for 24 h (two INRs ≥2 on two days). Both conditions — not one.
Warfarin closes the factory. It does not empty the warehouse. Factor VII sells out in a day — so the INR rises on day 2 — but prothrombin (II) takes 3 days just to drop by half. Until the old II is gone, the INR lies: the number looks therapeutic, the patient is not protected. And protein C (the "guard") leaves first → a short pro-clot window → warfarin skin necrosis, venous limb gangrene in HIT.
- AF (no acute clot): start warfarin alone — no heparin overlap needed.
- Mechanical valve after surgery, or acute VTE: overlap with UFH or LMWH (5-and-2).
- Day 3 rule of thumb: INR jumps ≥1 unit in a day, or is >2 by day 3 → sensitive patient → cut the dose.
Maintenance — change the weekly dose, not the daily dose
US warfarin tablet colors (mg). Asking "what color is your pill?" catches many dose errors at admission. Same colors for all US generics.
| INR (target 2–3) | Action |
|---|---|
| <1.5 | ↑ weekly dose 10–20% (consider 1 extra dose) |
| 1.5–1.9 | ↑ weekly dose 5–10% |
| 2.0–3.0 | No change |
| 3.1–3.9 | ↓ weekly dose 5–10% |
| 4.0–4.9 | Hold 1 dose, then ↓ 10% |
| ≥5 | See High INR below |
- Single INR off by ≤0.5 with a clear reason (missed dose, one antibiotic course) in a stable patient → no dose change, recheck in 1–2 weeks.
- After a dose change, the new INR settles in ~5–7 days — do not chase it every day in clinic.
- 5 mg daily = 35 mg/week. +10% ≈ 37.5 mg → "5 mg daily, 7.5 mg on Mondays."
- −10% ≈ 32.5 mg → "5 mg daily, 2.5 mg on Mondays."
- Keep one tablet strength (cut in half if needed). Two strengths at home = dosing errors.
INR detective — why did it change?
Ask the "INR interview": missed or extra doses · new drugs (antibiotics!) · diet (greens, shakes, tube feeds) · alcohol · illness (diarrhea, fever, HF congestion → liver) · thyroid.
Fluconazole (all azoles) · Amiodarone · TMP-SMX · Metronidazole · Acetaminophen (>2 g/day for days) · Ciprofloxacin / clarithromycin - Amiodarone: cut warfarin 25–50% when you start it. Effect builds over weeks → weekly INR for 6–8 weeks. - Metronidazole, fluconazole, TMP-SMX: consider a 10–25% cut and an INR in 3–5 days.
INR goes DOWN with: rifampin (huge), carbamazepine, phenytoin, phenobarbital, St John's wort, more vitamin K (greens, Ensure-type shakes, tube feeds), missed doses. Vitamin K diet = steady, not zero.
High INR & bleeding — reversal
⌄
- INR above range, <4.5No bleedingHold 0–1 dose · lower weekly dose 5–15% · recheck in 3–7 days
- INR 4.5–10No bleedingHold 1–2 doses · no routine vitamin K (1–2.5 mg PO if high bleed risk) · INR in 24–48 h
- INR >10No bleedingHold · vitamin K 2.5–5 mg PO · INR in 24 h · resume lower dose
- Major or life-threatening bleedAny INRStop · 4F-PCC + vitamin K 5–10 mg IV · FFP only if no PCC · find the source
- 4F-PCC (Kcentra) — works in minutes:
| INR | Dose | Max |
|---|---|---|
| 2 to <4 | 25 U/kg | 2500 U |
| 4–6 | 35 U/kg | 3500 U |
| >6 | 50 U/kg | 5000 U |
Many hospitals use a fixed dose (e.g. 1000–1500 U, 2000 U for ICH). Recheck INR 15–60 min after. - Always add vitamin K 5–10 mg IV (slow, over 20–30 min). PCC lasts only ~6–8 h; vitamin K keeps the INR down. - Vitamin K route: IV acts in ~4–6 h (full ~24 h) · PO in ~24 h · avoid SC (unpredictable) and IM (hematoma). - FFP only if no PCC: ~10–15 mL/kg — big volume, slow, partial. - Surgery tomorrow and INR still >1.5 → vitamin K 1–2.5 mg PO today.
| Drug | Reversal |
|---|---|
| Dabigatran | Idarucizumab 5 g IV (2 × 2.5 g). Dialysis also removes it |
| Apixaban, rivaroxaban, edoxaban | 4F-PCC 50 U/kg (or fixed 2000 U per protocol). Andexanet: withdrawn from the US Dec 2025 (more thrombosis in ANNEXA-I) |
| Any DOAC taken <2–4 h ago | Activated charcoal if airway safe |
- Last dose and CrCl tell you how much drug is left. Normal PT/aPTT does not prove a DOAC is gone. Drug-specific anti-Xa (apixaban/rivaroxaban) or dilute thrombin time (dabigatran) if available.
| Drug | Reversal |
|---|---|
| UFH | Protamine 1 mg / 100 U given in the last 2–3 h (max 50 mg) |
| Enoxaparin | Protamine 1 mg / 1 mg (<8 h) · 0.5 mg / 1 mg (8–12 h) — partial |
| Fondaparinux | No antidote — supportive; PCC/rFVIIa in extreme cases |
| Argatroban / bivalirudin | Stop — short half-life (≈45 min / 25 min) |
Most patients need their anticoagulant again. Discuss early with GI/neurosurgery. Typical timing: GI bleed ~7–14 days, ICH ~4–8 weeks (case by case). Not restarting is also a risk — strokes and clots.
Bridging & procedures
⌄
Warfarin interruption — the timeline
Last warfarin day −6 → no warfarin days −5 to −1 → INR day −1 (>1.5 → vitamin K 1–2 mg PO). LMWH 1 mg/kg q12h days −3 and −2, morning-only half-day dose on day −1. Warfarin restarts the evening of surgery. LMWH restarts 24 h after (low/moderate bleed) or 48–72 h after (high bleed) and stops when INR ≥2.
- Stop warfarin 5 days before (last dose on day −6). INR on day −1 → if >1.5, give vitamin K 1–2 mg PO.
- LMWH bridge (only VEST patients): start day −3 (therapeutic 1 mg/kg q12h). Last dose 24 h before surgery = half of the daily total (morning dose only).
- UFH bridge (CrCl <30): start when INR <2. Stop 4–6 h before surgery.
- After surgery: warfarin evening of surgery or next day (usual dose). Therapeutic LMWH: 24 h after low/moderate-bleed surgery, 48–72 h after high-bleed surgery. Stop LMWH when INR ≥2.
- PERIOP2 (2021): post-op bridging in AF/mechanical valve patients gave no benefit — another reason to be choosy.
DOAC interruption (PAUSE) — no bridging, no levels
| Drug | Low/moderate bleed risk | High bleed risk (incl. neuraxial) | Restart |
|---|---|---|---|
| Apixaban, rivaroxaban, edoxaban | Skip 1 day (last dose day −2) | Skip 2 days (last dose day −3) | 24 h (low) · 48–72 h (high) |
| Dabigatran, CrCl ≥50 | Skip 1 day | Skip 2 days | same |
| Dabigatran, CrCl 30–49 | Skip 2 days | Skip 4 days | same |
- High-bleed procedures: major cancer, cardiac, intracranial/spinal surgery, joint replacement, neuraxial anesthesia, kidney/liver biopsy, polypectomy >1 cm.
- After high-bleed surgery, give prophylactic dose LMWH/UFH until the full dose restarts.
Doses are typical adult doses. Check renal and hepatic function, weight, drug interactions and your hospital nomograms. Heparin targets depend on your lab — use the local anti-Xa/aPTT range.
Real-life ward tips
⌄
- Write the indication and target in every order and note: "Heparin — PE — anti-Xa 0.3–0.7". A wrong nomogram (VTE vs ACS) is a common error.
- No bolus after an ischemic stroke, a fresh post-op wound, or a recent bleed — start the drip at the rate only.
- Patient came in on apixaban and you start heparin? Use aPTT for 2–3 days — the anti-Xa will read falsely high and the drip gets turned down for nothing.
- "Heparin resistance" on aPTT? Send an anti-Xa before you go above 35,000 U/day. High factor VIII in sick patients makes the aPTT look low.
- Platelets dropping on day 5–10 of heparin → 4Ts score → HIT. Do not "just switch to enoxaparin" — it cross-reacts.
- Admitted with INR 6 and no bleeding? Hold warfarin. Do not reflexively give vitamin K 10 mg IV — you will make the patient warfarin-resistant for a week.
- INR suddenly high on antibiotics? It is usually the antibiotic plus poor intake. Hold one dose, recheck, and tell the clinic at discharge.
- Discharge on warfarin: write the weekly dose, the tablet strength, the next INR date (3–5 days), and who follows it. No follow-up plan = no warfarin.
- DOAC at discharge: check the dose against the indication (VTE loading dose done? AF reduction criteria?) and CrCl with actual weight. Check insurance cost before the patient leaves.
- Elderly fallers: a patient must fall ~295 times a year for the subdural risk to outweigh the stroke benefit of warfarin in AF (Man-Son-Hing 1999). Falls alone are not a contraindication.
- Liver disease: the INR shows liver synthesis, not bleeding risk. Do not "correct" an INR of 2 with FFP before a paracentesis.
- Combined with antiplatelets (after PCI): keep triple therapy short (often ≤1 week), then DOAC + clopidogrel. Add a PPI.
Pitfalls
⌄
- Using the ACS nomogram for a PE (under-treats) or the VTE nomogram for ACS (over-treats).
- Stopping heparin when the INR hits 2 on day 3 — the 5-and-2 rule needs both.
- Warfarin started alone for an acute VTE, or in HIT before platelets recover.
- Bridging AF patients — more bleeding, no fewer strokes.
- Bridging DOACs — never needed.
- Apixaban 2.5 mg BID for AF because of one criterion (age or Cr) → under-dosing → strokes.
- Rivaroxaban 15/20 mg without food (about one-third less absorbed).
- DOAC for a mechanical valve or triple-positive APS.
- Forgetting to restart anticoagulation after the procedure ("held for surgery" stays on the MAR for a week).
- SC vitamin K — slow and unpredictable.
Board corner
⌄
| Stem | Answer |
|---|---|
| New PE, 90 kg, IV heparin — bolus and rate? | 80 U/kg (7200 U) → 18 U/kg/h (1600 U/h) |
| NSTEMI, 110 kg, IV heparin bolus? | 60 U/kg but max 4000 U |
| On warfarin day 3 for DVT, INR 2.4 — stop enoxaparin? | No — needs ≥5 days and INR ≥2 for 24 h |
| Painful dark skin on the breast/thigh, day 4 of warfarin | Warfarin skin necrosis — protein C deficiency |
| INR 7, no bleeding | Hold warfarin, no routine vitamin K |
| INR 12, no bleeding | Hold + vitamin K 2.5–5 mg PO |
| INR 4, intracranial hemorrhage | 4F-PCC + vitamin K 10 mg IV |
| Bleeding on dabigatran | Idarucizumab |
| Life-threatening bleed on apixaban (US, 2026) | 4F-PCC (andexanet withdrawn) |
| AF, CHA₂DS₂-VASc 4, warfarin, colon resection — bridge? | No (BRIDGE trial) |
| Mechanical mitral valve, hip surgery | Stop warfarin 5 d, bridge with LMWH |
| Apixaban, hip replacement (high bleed) | Last dose 3 days before (skip 2 days); no bridge |
| AF + mechanical valve — best drug? | Warfarin (DOACs harm — RE-ALIGN) |
| Triple-positive APS + DVT | Warfarin INR 2–3 |
| Started amiodarone, INR rises from 2.5 to 4.8 | CYP2C9 inhibition → cut warfarin 25–50% |
| On rifampin, INR stuck at 1.3 on 15 mg/day | CYP induction → much higher warfarin dose or change the antibiotic (DOACs also interact) |
| Pregnant woman with new DVT | LMWH (warfarin teratogenic, DOAC not used) |
| aPTT does not rise on 40,000 U/day heparin | Check anti-Xa, then antithrombin level |
References
⌄
- Stevens SM, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline. Chest. 2021;160:e545.
- Douketis JD, et al. Perioperative management of antithrombotic therapy: an ACCP clinical practice guideline. Chest. 2022;162:e207.
- Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation. 2024;149:e1.
- Van Gelder IC, et al. 2024 ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2024;45:3314.
- Otto CM, et al. 2020 ACC/AHA guideline for the management of valvular heart disease. Circulation. 2021;143:e72.
- Tomaselli GF, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. JACC. 2020;76:594.
- Holbrook A, et al. Evidence-based management of anticoagulant therapy (CHEST 9th ed.). Chest. 2012;141:e152S.
- Martin KA, et al. Use of DOACs in patients with obesity: updated ISTH guidance. J Thromb Haemost. 2021;19:1874.
- Raschke RA, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med. 1993;119:874.
- Douketis JD, et al. BRIDGE — perioperative bridging anticoagulation in AF. NEJM. 2015;373:823.
- Douketis JD, et al. PAUSE — perioperative management of patients with AF receiving a DOAC. JAMA Intern Med. 2019;179:1469.
- Kovacs MJ, et al. PERIOP2 — postoperative LMWH bridging. BMJ. 2021;373:n1205.
- Birnie DH, et al. BRUISE CONTROL. NEJM. 2013;368:2084.
- Eikelboom JW, et al. RE-ALIGN — dabigatran in mechanical heart valves. NEJM. 2013;369:1206.
- Connolly SJ, et al. ANNEXA-I — andexanet for factor Xa inhibitor–associated ICH. NEJM. 2024;390:1745.
- FDA Safety Communication: Update on the safety of Andexxa (US sales ended Dec 22, 2025).
- Man-Son-Hing M, et al. Choosing antithrombotic therapy for elderly patients with AF who are at risk for falls. Arch Intern Med. 1999;159:677.